Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Analyst Ratings
Hold
4 Buy
14 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BMY Stock 12 Month Forecast
Average Price Target
$50.79
▲(8.34% Upside)
| Highest Price Target$65.00 | Average Price Target$50.79 | Lowest Price Target$34.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BMO Capital
$47
Hold
0.26%
Upside
Reiterated
08/22/25
Bernstein
―
Hold
―
Reiterated
08/17/25
TR | OpenAI - 4o
$47→$53
Buy
13.05%
Upside
Upgraded
08/14/25
Cantor Fitzgerald
$55→$45
Hold
-4.01%
Downside
Reiterated
08/13/25
Piper Sandler
$64
Buy
36.52%
Upside
Reiterated
08/11/25
Daiwa
$42
Hold
-10.41%
Downside
Downgraded
08/05/25
Leerink Partners
$55→$53
Buy
13.05%
Upside
Reiterated
08/04/25
UBS
$52→$46
Hold
-1.88%
Downside
Reiterated
08/01/25
Bank of America Securities
$56→$50
Hold
6.66%
Upside
Reiterated
08/01/25
Citi
$51→$47
Hold
0.26%
Upside
Reiterated
08/01/25
J.P. Morgan
$67→$65
Buy
38.65%
Upside
Reiterated
08/01/25
Truist Financial
―
Buy
―
Reiterated
08/01/25
TD Cowen
$54
Hold
15.19%
Upside
Reiterated
07/31/25
Morgan Stanley
$34
Sell
-27.47%
Downside
Reiterated
07/31/25
Sell Rating for Bristol-Myers Squibb Due to Overly Optimistic Estimates and Clinical Trial DelaysWe see risk to 2026+ estimates. BMY shares traded down -5.7% on 7/31 (vs. S&P500 -0.4%) likely driven by questions around the quality of the 2Q beat (see our first take HERE and more below) and BMY's commentary on the earnings call noting that they are conducting clinical trial site reviews, which could impact data timelines for the Ph3 trial. For context the company’s prior guidance for data timing was late 3Q/ early 4Q, but mgmt noted that the data are still expected by YE25. We followed up with IR who indicated that the company elected to take a look across all of their ongoing clinical trials in light of recent trial failures (Camzyos ODYSSEY-HCM, Cobenfy ARISE and Reblozyl INDEPENDENCE) to ensure that probability of success for future trials is as high as possible, and this is not solely focused on ADEPT-2.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BMO Capital
$47
Hold
0.26%
Upside
Reiterated
08/22/25
Bernstein
―
Hold
―
Reiterated
08/17/25
TR | OpenAI - 4o
$47→$53
Buy
13.05%
Upside
Upgraded
08/14/25
Cantor Fitzgerald
$55→$45
Hold
-4.01%
Downside
Reiterated
08/13/25
Piper Sandler
$64
Buy
36.52%
Upside
Reiterated
08/11/25
Daiwa
$42
Hold
-10.41%
Downside
Downgraded
08/05/25
Leerink Partners
$55→$53
Buy
13.05%
Upside
Reiterated
08/04/25
UBS
$52→$46
Hold
-1.88%
Downside
Reiterated
08/01/25
Bank of America Securities
$56→$50
Hold
6.66%
Upside
Reiterated
08/01/25
Citi
$51→$47
Hold
0.26%
Upside
Reiterated
08/01/25
J.P. Morgan
$67→$65
Buy
38.65%
Upside
Reiterated
08/01/25
Truist Financial
―
Buy
―
Reiterated
08/01/25
TD Cowen
$54
Hold
15.19%
Upside
Reiterated
07/31/25
Morgan Stanley
$34
Sell
-27.47%
Downside
Reiterated
07/31/25
Sell Rating for Bristol-Myers Squibb Due to Overly Optimistic Estimates and Clinical Trial DelaysWe see risk to 2026+ estimates. BMY shares traded down -5.7% on 7/31 (vs. S&P500 -0.4%) likely driven by questions around the quality of the 2Q beat (see our first take HERE and more below) and BMY's commentary on the earnings call noting that they are conducting clinical trial site reviews, which could impact data timelines for the Ph3 trial. For context the company’s prior guidance for data timing was late 3Q/ early 4Q, but mgmt noted that the data are still expected by YE25. We followed up with IR who indicated that the company elected to take a look across all of their ongoing clinical trials in light of recent trial failures (Camzyos ODYSSEY-HCM, Cobenfy ARISE and Reblozyl INDEPENDENCE) to ensure that probability of success for future trials is as high as possible, and this is not solely focused on ADEPT-2.
Best Analysts Covering Bristol-Myers Squibb
1 Month
xxx
Success Rate
11/24 ratings generated profit
Average Return
+0.50%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 45.83% of your transactions generating a profit, with an average return of +0.50% per trade.
3 Months
xxx
Success Rate
15/24 ratings generated profit
Average Return
+2.25%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +2.25% per trade.
1 Year
Success Rate
19/24 ratings generated profit
Average Return
+8.26%
reiterated a sell rating last month
Copying Terence Flynn's trades and holding each position for 1 Year would result in 79.17% of your transactions generating a profit, with an average return of +8.26% per trade.
2 Years
xxx
Success Rate
19/24 ratings generated profit
Average Return
+11.59%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 79.17% of your transactions generating a profit, with an average return of +11.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BMY Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
1
1
1
Buy
15
9
10
14
19
Hold
42
40
50
40
42
Sell
4
4
3
3
3
Strong Sell
0
0
0
0
0
total
61
53
64
58
65
Each month's total comprises the sum of three months' worth of ratings.
BMY Financial Forecast
BMY Stock Forecast FAQ
What is BMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 50.79.
What is BMY’s upside potential, based on the analysts’ average price target?
Bristol-Myers Squibb has 8.34% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BMY a Buy, Sell or Hold?
Bristol-Myers Squibb has a consensus rating of Hold which is based on 4 buy ratings, 14 hold ratings and 1 sell ratings.
What is Bristol-Myers Squibb’s price target?
The average price target for Bristol-Myers Squibb is 50.79. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $34.00. The average price target represents 8.34% Increase from the current price of $46.88.
The highest analyst price target is $65.00 ,the lowest forecast is $34.00. The average price target represents 8.34% Increase from the current price of $46.88.
What do analysts say about Bristol-Myers Squibb?
Bristol-Myers Squibb’s analyst rating consensus is a Hold. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of BMY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.